Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Schiff RFID

This article was originally published in The Tan Sheet

Executive Summary

In a Feb. 23 announcement of its partnership with IBM for a radio frequency identification pilot Armonk, N.Y.-based Schiff Nutrition International says it is the first mid-size manufacturer to execute an RFID program and it gives the firm a "competitive advantage" in the market and illustrates RFID is "sustainable for small- and medium-sized businesses." At IBM's RFID facility in Raleigh, N.C., Schiff tested "which combinations of tags and readers worked best for its products and perfected used of RFID on mixed pallets, while spinning them in a pallet wrapper," a press release says. "This enables the seamless continuation of the supply chain, without slowing it down to read the tags, a critical requirement for Schiff," the firm says. IBM will continue to deliver services to Schiff through 2007...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100260

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel